Publications | Cancer type | Cell lines | Tissues | Anticancer drugs | Notes |
---|---|---|---|---|---|
Sun [11] | Non-small cell lung cancer | No | Yes | Platinum; paclitaxel | High level of stathmin exhibits poor response to chemotherapy |
Lin [78] | Yes | No | Taxol | Inhibition of stathmin expression increases sensitivity to taxol and promotes cellular apoptosis in NCI-H1299 cells | |
Lin [79] | Yes | No | Taxol | ERK-mediated stathmin is involved in taxol resistance of NCI-H1299 cells; blockage of ERK signal improves sensitivity of tumor cells to taxol | |
Han [80] | Yes | No | Paclitaxel | Inhibition of stathmin and Bcl-2 expression can sensitize lung cancer cells to paclitaxel | |
Feng [82] | Esophageal squamous carcinoma | Yes | No | Paclitaxel | Combined chemotherapeutic agent paclitaxel and stathmin siRNA can potentially enhance the therapeutic outcomes of paclitaxel in treating esophageal squamous cell cancer (ESCC) |
Wang [16] | Yes | No | Paclitaxel | Silencing of stathmin gene can increase sensitivity of ESCC to paclitaxel and vincristine through G2/M phase block | |
Zhu [81] | Yes | No | Paclitaxel | Stathmin silencing by siRNA enhances sensitivity of esophageal cancer cells Eca-109 to paclitaxel and induces apoptosis | |
Balasubramani [83] | Breast cancer | Yes | No | Taxol | Stathmin overexpression protects the cells from taxol-induced abnormal mitoses, and thus induces taxol resistance |
Miceli [48] | Yes | No | Taxol | Combination of anti-stathmin therapy and taxol has a more profound inhibition of tumorigenicity | |
Oda [84] | Yes | No | Zoledronic acid; gefitinib | Down-regulation of stathmin contributes to the effect that combined treatment of Zoledronic acid (Zol) and gefitinib inhibits both invasion and cell proliferation of the bone-seeking clone of breast cancer | |
Meng [61] | Gastric cancer | Yes | No | Docetaxel | Stathmin siRNA can improve the chemosensitivity of gastric cancer cells to docetaxel and promote apoptosis |
Li [24] | Yes | No | Docetaxel | Stathmin mediates docetaxel resistance in transcription factor forkhead box protein M1 (FOXM1)FOXM1-silenced gastric cancer cells | |
Liu [25] | Yes | No | Docetaxel | Inhibition of stathmin enhances the inhibitory effects of docetaxel on the proliferation of gastric cancer cells | |
Werner [85] | Endometrial carcinoma | Yes | Yes | Paclitaxel | Knock-down of stathmin improves sensitivity to paclitaxel in endometrial carcinoma cells |
Wosnitzer [35] | Bladder cancer | No | Yes | Taxane | Bladder cancer those who have tumors with low tau/stathmin protein expression show a better response to taxane |
Mitra [86] | Retinoblastoma | Yes | Yes | Paclitaxel | Inhibition of stathmin enhances the cytotoxic effect of paclitaxel |
Song [63] | Glioma | Yes | No | Temozolomide | Stathmin silencing inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from glioma cells |
Feng [87] | Osteosarcoma | Yes | No | Arsenic trioxide; doxorubicin | Down-regulation of stathmin significantly enhances reversion of ADM resistance in MG63/dox by As2O3 |
Wu [88] | Colorectal cancer | Yes | No | 5-fluorouracil | Silencing of stathmin significantly improves chemoresponse to the classical colorectal cancer therapeutic agent, 5-FU |
Watanabe [18] | Extrahepatic cholangiocarcinoma | Yes | Yes | Paclitaxel | Silencing of stathmin inhibits proliferation and increases sensitivity of extrahepatic cholangiocarcinoma cells to paclitaxel |